1039 ET - Regeneron Pharmaceuticals' Eylea franchise has known headwinds, but the magnitude of its miss in the U.S. may further rattle investors, say Evercore ISI analysts in a research note. The drug maker said sales of Eylea, both the original formulation and HD version, were affected by inventory issues and competition from biosimilars. What was not expected was yet another complete response letter from the FDA for the prefilled syringe in Eylea HD, say the analysts. "We expect a negative reaction as frustrations mount with the company's regulatory execution," say the analysts. Shares decline 7.1% to $567.62, making it the worst performer in the S&P 500 and Nasdaq 100. (denny.jacob@wsj.com; @pennedbyden)
(END) Dow Jones Newswires
April 29, 2025 10:39 ET (14:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.